1. What’s happening
Early indicators from rollouts of two obesity pills suggest Eli Lilly and Novo Nordisk are addressing operational issues that have hampered earlier GLP-1 commercialization.
2. What’s the big deal
Shipping started for Eli Lilly’s Foundayo (orforglipron) obesity pill on Monday, four business days after Food and Drug Administration approval, setting up a toe-to-toe match against an oral version of Wegovy (semaglutide), launched by Novo in January. As the launches demonstrate, both drugmakers are rectifying operational snafus and those that have hampered the broader GLP-1 market:
- Speed to patient: Novo was late to capitalize on direct-to-consumer sales of its obesity drugs at lowered cash prices (Lilly's DTC platform reached 1 million patients last year), but Novo’s oral semaglutide has enjoyed the best launch of any obesity drug to date, an accomplishment which analysts attribute to early availability of the pill through the drugmaker’s NovoCares DTC pharmacy for cash-paying customers.
- Stockpiling supply: Lilly built a $1.5 billion inventory to avoid the shortages experienced with other GLP-1 drugs, including its own Zepbound/Mounjaro shots (and Novo’s Wegovy/Ozempic injections), and has expanded its manufacturing capacity -- moves designed to enable launching in multiple markets simultaneously.
- Accelerated review: The FDA said Foundayo marked the first new molecular entity approved under a priority voucher program and the fastest NME approval since 2002, coming just 50 days after Lilly’s filing and 10 months sooner than the agency’s initial target decision date.
3. What’s at stake
As Lilly looks to carve out a position for Foundayo, as well as forthcoming experimental pill retatrutide (aka “Triple G”), Novo sees its oral semaglutide and other new formulations as key to its comeback. After the Danish drugmaker fell behind Lilly in the overall weight-loss market last year, it’s working aggressively to make up ground, including...
- This week’s launch of a high-dose formulation of the Wegovy shot (Wegovy HD) priced to undercut most doses of Zepbound.
- Last week’s launch of a subscription program, through telehealth partners like Ro and WeightWatchers, with lower monthly prices for the Wegovy pill and shot when patients sign up for several months of treatment.
- Boosting its 2025 sales and distribution spend by 7% to roughly $10 billion, which the company noted was mostly related to "Wegovy launches and promotional activities,” according to a recent regulatory filing.
4. What it means for commercial execs
The rollouts show that "direct” has become de rigueur in obesity commercialization, as have comparable cash prices.
- Lilly is launching Foundayo on DTC site LillyDirect first, followed by pharmacies and telehealth providers, and oral Wegovy added availability through Hims & Hers last month, as online cash-pay services become part and parcel of both drugs’ sales push.
- Those opting for self-pay can access either Lilly’s or Novo’s obesity pills starting at $149 per month for the lowest dose.
- Lilly’s marketing will emphasize convenience, specifically that the pill can be taken any time of day without food or water restrictions, whereas Wegovy must be taken on an empty stomach and 30 minutes before eating or drinking.
5. What’s next
Analysts predict Lilly will outgain Novo for a 60% share of the daily oral segment of the weight-loss drug market by 2030, but the two market leaders will continue to be aggressive in gaining an edge in the broader obesity treatment race.
- Lilly execs have expressed interest in creating a subscription program, following Novo’s efforts.
- Both companies have spent billions on obesity-related acquisitions and licensing deals, both in upfront cash payments and milestone-based payments.
- Medicare enrollees are expected to gain broad access to obesity treatments starting this month, which should benefit both companies.
- Foundayo and the Wegovy pill are among several upcoming launches that show oral drugs moving from a niche advantage to a market expansion strategy.